Gwendolyn Binder - Jun 20, 2023 Form 4 Insider Report for Cabaletta Bio, Inc. (CABA)

Role
President, Science & Technology
Signature
By: /s/ Michael Gerard, as Attorney-in-Fact
Stock symbol
CABA
Transactions as of
Jun 20, 2023
Transactions value $
-$131,815
Form type
4
Date filed
6/21/2023, 04:38 PM
Previous filing
Jan 10, 2024
Next filing
Jul 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CABA Common Stock Options Exercise $11.1K +11K +55% $1.01* 31K Jun 20, 2023 Direct F1
transaction CABA Common Stock Sale -$143K -11K -35.48% $12.99 20K Jun 20, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CABA Stock Option (Right to Buy) Options Exercise $0 -11K -5.83% $0.00 178K Jun 20, 2023 Common Stock 11K $1.01 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 - $13.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

Remarks:

President, Science & Technology